Synthesis of (6R)- And (6S)-5,10-dideazatetrahydrofolate oligo-γ-glutamates: Kinetics of multiple glutamate ligations catalyzed by folylpoly-γ-glutamate synthetase

Organic and Biomolecular Chemistry

Volumn 3, Issue 18, 2005, Pages 3388-3398

  Tomsho, John W ^a   McGuire, John J ^b   Coward, James K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUGS; GLUTAMIC ACID; MICHAELIS-MENTEN KINETICS; STEADY-STATE KINETIC CONSTANTS;

AMINO ACIDS; CATALYSIS; DISEASE CONTROL; DRUG PRODUCTS; ENZYME INHIBITION; ENZYMES; REACTION KINETICS; SYNTHESIS (CHEMICAL); TUMORS;

OLIGOMERS;

FOLYLPOLYGLUTAMATE SYNTHASE; PEPTIDE SYNTHASE; PTEROPTIN;

ARTICLE; CATALYSIS; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; KINETICS; METABOLISM; SYNTHESIS;

CATALYSIS; KINETICS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PEPTIDE SYNTHASES; PTEROYLPOLYGLUTAMIC ACIDS; SUBSTRATE SPECIFICITY;

EID: 26444508495     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b505907k     Document Type: Article

References (55)

1. J. J. McGuire and J. R. Bertino, Mol. Cell Biochem., 1981, 38, 19-48.
2. J. J. McGuire, and J. K. Coward, in Folates and Pterins, ed. R. L. Blakley and S. J. Benkovic, John Wiley & Sons, New York, 1984, pp. 135-190.
3. B. Shane, Vitamins and Hormones - Advances in Research and Applications, 1989, 45, 263-335.
4. L. G. Mendelsohn, J. F. Worzalla, and J. M. Walling, in Antifolate Drugs in Cancer Therapy, ed. A. L. Jackman, 1999, Humana, Totowa, NJ, pp. 261-280.
5. J. Adams and P. J. Elliott, Oncogene, 2000, 19, 6687-6692.
6. J. J. McGuire, Curr. Pharm. Des., 2003, 9, 2593-2613.
7. W. T. Purcell and D. S. Ettinger, Curr. Oncol. Rep., 2003, 5, 114-125.
8. G. P. Beardsley, B. A. Moroson, E. C. Taylor and R. G. Moran, J. Biol. Chem., 1989, 264, 328-333.
9. G. P. Beardsley, E. C. Taylor, G. B. Grindey, and R. G. Moran, in Chemistry and Biology of the Pteridines 1986, ed. B. A. Cooper and V. M. Whitehead, Walter de Gruyter & Co., Berlin, 1986, pp. 953-957.
10. R. G. Moran, S. W. Baldwin, E. C. Taylor and C. Shih, J. Biol. Chem., 1989, 264, 21047-21051.
11. G. Pizzorno, J. A. Sokoloski, A. R. Cashmore, B. A. Moroson, A. D. Cross and G. P. Beardsley, Mol. Pharmacol., 1991, 39, 85-89.
12. P. C. Sanghani and R. G. Moran, Protein Expression Purif., 2000, 18, 36-45.
13. L. L. Habeck, S. H. Chay, R. C. Pohland, J. F. Worzalla, C. Shih and L. G. Mendelsohn, Cancer Chemother. Pharmacol., 1998, 41, 201-209.
14. E. C. Taylor, P. J. Harrington, S. R. Fletcher, G. P. Beardsley and R. G. Moran, J. Med. Chem., 1985, 28, 914-921.
15. L. L. Habeck, L. G. Mendelsohn, C. Shih, E. C. Taylor, P. D. Colman, L. S. Gossett, T. A. Leitner, R. M. Schultz, S. L. Andis and R. G. Moran, Mol. Pharmacol., 1995, 48, 326-333.
16. S. W. Baldwin, A. Tse, L. S. Gossett, E. C. Taylor, A. Rosowsky, C. Shih and R. G. Moran, Biochemistry, 1991, 30, 1997-2006.
17. H. M. Faessel, H. K. Slocum, R. C. Jackson, T. J. Boritzki, Y. M. Rustum, M. G. Nair and W. R. Greco, Cancer Res., 1998, 58, 3036-3050.
18. J. J. McGuire, in Antifolate Drugs in Cancer Therapy, ed. A. L. Jackman, 1999, Humana, Totowa, NJ, pp. 339-363.
19. E. Liani, L. Rothem, M. A. Bunni, C. A. Smith, G. Jansen and Y. G. Assaraf, Int. J. Cancer, 2003, 103, 587-599.
20. E. C. Taylor, J. Heterocycl. Chem., 1990, 27, 1-12.
21. I. Durucasu, Heterocycles, 1993, 35, 1527-1545.
22. E. C. Taylor, G. S. K. Wong, S. R. Fletcher, P. J. Harrington, G. P. Beardsley, and C. J. Shih, in Chemistry and Biology of Pteridines 1986, ed. B. A. Cooper and V. M. Whitehead, Walter de Gruyter & Co., Berlin, 1986, pp. 61 64.
23. C. J. Barnett, T. M. Wilson, S. R. Wendel, M. J. Winningham and J. B. Deeter, J. Org. Chem., 1994, 59, 7038-7045.
24. J. Luo, M. D. Smith, D. A. Lantrip, S. Wang and P. L. Fuchs, J. Am. Chem. Soc., 1997, 119, 10004-10013.
25. N. Valiaeva, D. Bartley, T. Konno and J. K. Coward, J. Org. Chem., 2001, 66, 5146-5154.
26. E. C. Taylor, R. Chaudhari and K. Lee, Invest. New Drugs, 1996, 14, 281-285.
27. A. D. Cross, H. Morimoto, P. G. Williams and G. P. Beardsley, J. Labelled Compd. Radiopharm., 1991, 29, 753-763.
28. C. L. Krumdieck and C. M. Baugh, Biochemistry, 1969, 8, 1568-1572.
29. J. Meienhofer, P. M. Jacobs, H. A. Godwin and I. H. Rosenberg, J. Org. Chem., 1970, 35, 4137-4140.
30. M. R. Mejillano, H. Jahansouz, T. O. Matsunaga, G. L. Kenyon and R. H. Himes, Biochemistry, 1989, 28, 5136-5145.
31. H. A. Godwin, I. H. Rosenberg, C. R. Ferenz, P. M. Jacobs and J. Meienhofer, J. Biol. Chem., 1972, 247, 2266-2271.
32. J. K. Coward, K. N. Parameswaran, A. R. Cashmore and J. R. Bertino, Biochemistry, 1974, 13, 3899-3903.
33. C. N. C. Drey and G. P. Priestly, J. Chem. Res., 1979, 2, 3055-3071.
34. J. R. Piper, G. S. McCaleb and J. A. Montgomery, J. Med. Chem., 1983, 26, 291-294.
35. L. D'Ari and J. C. Rabinowitz, Methods Enzymol, 1985, 113, 169-182.
36. W. P. Jencks, and J. Regenstein, in CRC Handbook of Biochemistry and Molecular Biology, ed. G. D. Fasman, 1975, CRC Press, Inc., Boca Raton, FL, pp. 305-351.
37. G. X. B. Ma, R. A. Batey, S. D. Taylor, G. Hum and J. B. Jones, Synth. Commun., 1997, 27, 2445-2453.
38. W. Chan, and P. White, Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press Inc., New York, 2000.
39. M. Dixon, and E. C. Webb, Enzymes (3rd edn), Academic Press, New York, 1979. Eqn (2) is valid under our assay conditions of fixed, saturating concentrations of ATP and glutamate.
40. V. Leskovac, Comprehensive Enzyme Kinetics, Kluwer Academic/Plenum Publishers, New York, 2003.
41. X. Sun, A. L. Bognar, E. N. Baker and C. A. Smith, Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 6647-6652.
42. X. Sun, J. A. Cross, A. L. Bognar, E. N. Baker and C. A. Smith, J. Mol. Biol, 2001, 310, 1067-1078.
43. M. Mathieu, G. Debousker, S. Vincent, F. Viviani, N. Bamas-Jacques and V Mikol, J. Biol. Chem., 2005, 280, 18916-18922.
44. Additional reducing agent was not included in these reactions, as early experiments with hFPGS expressed in E. coli indicated no measurable effect of the presence of reducing agent on enzyme activity or product distribution. However, the reactions that utilized enzyme expressed in E. coli had a final concentration of 4 mM 2-mercaptoethanol due to its presence in the enzyme storage buffer. In contrast, the reactions in which enzyme expressed in SF-9 insect cells had been used, the final concentration of 2-mercaptoethanol was 0.4 mM. Subsequently, it was determined that additional reducing agent (100 mM 2-mercaptoethanol or 5 mM dithiothreitol) increased the chain-length of the polyglutamate products produced only for the hFPGS expressed in SF-9 insect cells. This observation suggests that the addition of reducing agent to the assays shown in Fig. 3 would intensify the observed substrate inhibition.
45. L. Chen, H. Qi, J. Korenberg, T. A. Garrow, Y J. Choi and B. Shane, J. Biol. Chem., 1996, 271, 13077-13087.
46. R. Banerjee, J. J. McGuire, B. Shane and J. K. Coward, Biochemistry, 1988, 27, 9062-9070.
47. J. W. Tomsho, Ph.D. dissertation, University of Michigan, Ann Arbor, MI, 2005.
48. I. H. Segel, Enzyme Kinetics, John Wiley & Sons, New York, 1975.
49. J. J. McGuire, P. Hsieh, J. K. Coward and J. R. Bertino, J. Biol. Chem., 1980, 255, 5776-5788.
50. A. Gangjee, J. Yu, R. L. Kisliuk, W. H. Haile, G. Sobrero and J. J. McGuire, J. Med. Chem., 2003, 46, 591-600.
51. M. M. Bradford, Anal. Biochem., 1976, 72, 248-254.
52. P. J. Bagley and J. Selhub, Methods Enzymol., 1997, 281, 16-25.
53. C. J. Barnett and T. M. Wilson, Tetrahedron Lett., 1989, 30, 6291-6294.
54. C. J. Barnett, and T. M. Wilson, in Chemistry and Biology of Pteridines 1989, ed. H.-C. Curtius, S. Ghisla and N. Blau, Walter de Gruyter, Berlin, 1990, pp. 102-105.
55. J. J. McGuire, P. Hsieh, J. K. Coward, and J. R. Bertino, in Folyl and Antifolyl Polyglutamates, ed. I. D. Goldman, B. A. Chabner, and J. R. Bertino, Plenum Press, New York, 1983, pp. 199-214.